We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current TEVJF market cap is 16.73B. The company's latest EPS is USD -0.4986 and P/E is -29.92.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 16.89B | 16.66B | 15.88B | 14.93B | 15.85B |
| Operating Income | -443M | -3.58B | 1.71B | -2.12B | 408M |
| Net Income | -999M | -3.99B | 417M | -2.35B | -559M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 57.47B | 50.64B | 47.67B | 44.01B | 43.48B |
| Total Liabilities | 42.41B | 39.58B | 36.42B | 35.32B | 35.35B |
| Total Equity | 15.06B | 11.06B | 11.24B | 8.69B | 8.13B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 748M | 1.22B | 798M | 1.59B | 1.37B |
| Investing | 1.36B | 863M | 1.52B | 656M | 968M |
| Financing | -1.93B | -1.89B | -2.17B | -1.49B | -1.91B |
| Market Cap | 16.73B |
| Price to Earnings Ratio | -29.92 |
| Price to Sales Ratio | 1.06 |
| Price to Cash Ratio | 5.19 |
| Price to Book Ratio | 2.06 |
| Dividend Yield | - |
| Shares Outstanding | 1.12B |
| Average Volume (1 week) | 300 |
| Average Volume (1 Month) | 231 |
| 52 Week Change | 75.32% |
| 52 Week High | 16.71 |
| 52 Week Low | 7.03 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Teva Pharmaceutical Industries Ltd (PK) |
| Address |
124 dvora hanevi’a st tel aviv, center 6944020 |
| Website | https://www.tevapharm.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
